Singapore markets closed

Straits Times Index
3,307.90
-6.15(-0.19%)
Nikkei
38,946.93
-122.75(-0.31%)
Hang Seng
19,220.62
-415.60(-2.12%)
FTSE 100
8,416.45
-7.75(-0.09%)
Bitcoin USD
69,405.63
-397.48(-0.57%)
CMC Crypto 200
1,503.64
+15.10(+1.01%)

PROK May 2024 2.500 put

OPR - OPR Delayed price. Currency in USD

Add to watchlist

0.3500

0.0000

(0.00%)

As of 11:29AM EDT. Market open.

GlobeNewswire
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024
WINSTON-SALEM, N.C., May 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), will host a virtual KOL event on Tuesday, May 28, 2024 at 8:00 AM ET, featuring Steven G. Coca, DO, MS (Icahn School of Medicine at Mount Sinai) and Arnold L. Silva, MD, PhD (University of Arizona) who will discuss the unmet medical need and current treatment landscape for patients
Simply Wall St.
We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
GuruFocus.com
ProKidney Corp Reports First Quarter 2024 Financial Results
Performance Analysis and Future Outlook Amidst Ongoing Clinical Developments